Regulatory controls on local collection and processing of autologous cells present a major challenge to clinics that want to provide individualized therapies onsite. What does the pharmaceutical industry need to know — and, more importantly, do — to overcome it?
Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer and inflammatory diseases, recently announces the enrolment of the first patient in its phase IIa clinical trial with milciclib, a novel inhibitor of cyclin-dependent kinases (CDKs), in patients with refractory hepatocellular carcinoma (“HCC”)
Piramal Pharma Solutions (PPS) is pleased to welcome Ash Stevens LLC as a part of the Piramal Group. Leveraging five decades of Ash Stevens’s operational experience and technical expertise, Piramal’s service offering now includes High Potency API (HPAPI) development and manufacturing capabilities. Located in Riverview, USA, our state-of the-art FDA licensed cGMP facility offers a full range of scale and containment options for high potency API manufacturing.
We conduct regular monthly online Exchanges – focused vertical market auctions, including Aviation Equipment, BioPharma, Broadcast Equipment, Electronic Manufacturing, IT, Metalworking & Machinery, Packaging & Processing, Printing, and Transportation. Each Exchange contains surplus assets from multiple industry-leading global corporations to small and medium sized companies, providing would-be buyers with a continuous supply of high-quality equipment.
At Finesse, our goal is to enable customers to quickly and efficiently manufacture innovative drugs and vaccines. The SmartRocker, SmartBag, SmartPuck and SmartReader combination brings next generation control and measurement to rocking bioreactor applications. A SmartRocker is controlled by a G3Lab™ Universal SmartController and Finesse TruBio® software. This turnkey package provides a complete solution for research, process development, or seed train production applications.
Comprehensive contract development. Reliable cGMP manufacturing. Gain a competitive advantage in both by choosing Patheon for your biopharmaceuticals and biosimilars. You’ll have access to end-to-end, fully integrated services for both drug substances and drug products, delivered on time and on budget. A simplified supply chain that accelerates development and keeps you ahead in the rapidly changing world of biologics.
Althea’s complete range of drug Process Development capabilities offers the tools to address your needs. We develop processes for producing small quantities of proteins for early testing or establish robust, reliable and scalable processes that enable a strong commercial advantage. Althea also provides access to a proprietary drug delivery platform, called Crystalomics® technology, for the development of alternative drug delivery formulations of second generation drug substances.
